![[Toyota Times] Century as a Brand, Lexus as Innovation: All the Details on Toyota's New Project!](https://businessfortnight.com/wp-content/uploads/2025/10/Toyota-Times-Century-as-a-Brand-Lexus-as-Innovation-All-218x150.jpg "[Toyota Times] Century as a Brand, Lexus as Innovation: All the Details on Toyota's New Project!")
BELLEVUE, Wash., Oct. 18, 2022 (GLOBE NEWSWIRE) — EMulate Therapeutics, a clinical-stage, life sciences, digital therapeutics firm creating protected, non-invasive, and extremely efficient remedies for cancers and different severe ailments, at this time introduced the publication of optimistic preclinical knowledge evaluating the use of its lightweight wearable machine that makes use of proprietary WAV information to ship particular low to ultra-low radio frequency power (ulRFE®) in validated murine fashions of ache. The outcomes reveal a statistically vital discount in visceral, neuropathic, and inflammatory ache in these fashions. The knowledge had been revealed in Electromagnetic Biology and Medicine and may be accessed right here.
The use of magnetic fields to have an effect on organic processes in residing techniques has been properly studied for the previous a number of a long time. Employing electromagnetic fields like ulRFE to result in therapeutic outcomes, nevertheless, is a more moderen growth. Successful ache discount from the software of ulRFE has potential to handle frequent points with present pharmacological normal of care, maybe the most salient of which is the potential for ulRFE to supply a relentless impact to the uncovered area, thus overcoming enzymatic, blood-brain and different boundaries to the supply of medicine to affected elements of the organic system, in addition to the results of supply, systemic dilution and clearance which might be skilled with historically administered medicine.
“We are thrilled to have the results of our latest study published and are encouraged by the positive results. The information we obtained from this study will inform the design of our future pre-clinical studies and will enable our clinical studies as we continue to explore the untapped potential of our ulRFE technology in the reduction of pain and other disease indications,” mentioned Chris Rivera, chief government officer of EMulate Therapeutics.
“We are encouraged by the results of this study that show our radio frequency energy WAV files consistently and specifically produced statistically significant effects in the pain models tested, in some cases to a greater effect than the reference drugs used to validate each model” mentioned Xavier Figueroa, Ph.D. principal scientist for EMulate Therapeutics. “These results suggest that the magnetic fields produced by our WAV files, and particularly those with frequencies below 10 kHz, can provide an efficacious reduction in pain sensation in these pain studies.”
About EMulate Therapeutics, Inc.
EMulate Therapeutics is a medical stage firm using its proprietary radio frequency power expertise (RFE) focused at the low and ultra-low ends of the RFE spectrum (ulRFE®) to supply protected and efficient therapeutic advantages particularly focused at sufferers’ underlying situations. The firm has generated encouraging human knowledge from sufferers stricken with glioblastoma and diffuse midline glioma and is making ready for pivotal (section III) research in every indication. It has additionally generated encouraging preclinical research in ache administration and psychological well being fashions and is making ready for preliminary human medical trials in every space. In addition, optimistic knowledge have been generated independently in animal well being (optimistic most cancers leads to over 20 completely different strong tumor sorts in canines (pets)), in addition to in bio-agriculture fashions. EMulate Therapeutics is the licensor of its proprietary expertise to Hapbee Technologies, Inc. (HAPB: TSVX). Hapbee is a industrial stage shopper wellness-wearable expertise firm spun out from EMulate in 2019. EMulate is the largest impartial shareholder in Hapbee and recipient of quarterly royalties from web gross sales.
About our ulRFE Device
EMulate Therapeutics (EMTx) has developed a non-sterile, non-invasive, non-thermal, non-ionizing, battery-powered, moveable investigational medical machine that makes use of low to ultra-low degree (DC-22kHz) frequencies to ship particular electromagnetic alerts to cut back ache sensations. The system emits a low energy magnetic subject (< 100 mG) that may be utilized domestically or globally, depending on the kind of therapeutic impact sought. The EMTX alerts are saved as WAV information on the machine and emitted through a cable to the hooked up antenna unit.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This press launch accommodates “forward-looking statements”. Forward-looking statements talk about issues that aren’t historic details. Because they talk about future occasions or situations, forward-looking statements might embrace phrases akin to “anticipate,” “believe,” “estimate,” “intend,” “could,” “should,” “would,” “may,” “seek,” “plan,” “might,” “will,” “expect,” “anticipate,” “predict,” “project,” “forecast,” “potential,” and “continue” or the negatives thereof or related expressions. Forward-looking statements communicate solely as of the date they’re made, are primarily based on numerous underlying assumptions and present expectations about the future and are usually not ensures of future efficiency. While we consider these assumptions and expectations to be affordable and made in good religion, assumed details or bases nearly at all times differ from the precise outcomes, and the variations between assumed details or expectations and precise outcomes may be materials, relying upon the circumstances. Where, in any forward-looking assertion, our administration expresses an expectation or perception as to future outcomes, such expectation or perception is expressed in good religion and is believed to have an inexpensive foundation. Such statements contain identified and unknown dangers, uncertainties and different elements that will trigger our precise outcomes, degree of exercise, efficiency or achievement to be materially completely different from the outcomes of operations or plans expressed or implied by such forward-looking statements. You are cautioned to not place undue reliance on these forward-looking statements, which communicate solely as of their dates.
We can’t predict all the dangers and uncertainties that will affect our business, monetary situation or outcomes of operations. Accordingly, the forward-looking statements on this press launch shouldn’t be thought to be representations that the outcomes or situations described in such statements will happen or that our aims and plans will likely be achieved. These forward-looking statements are discovered at numerous locations all through this press launch and will embrace data regarding potential or projected future outcomes of our operations, together with statements about potential acquisition or merger targets, methods or plans; business methods; prospects; future money flows; financing plans; plans and aims of administration; another statements relating to future acquisitions, future money wants, future operations, business plans and future monetary outcomes; and another statements that aren’t historic details.
Except to the extent required by legislation, we undertake no obligation to replace or revise any forward-looking statements, whether or not because of this of new data, future occasions, a change in occasions, situations, circumstances or assumptions underlying such statements, or in any other case.
Investor Contact
David Matteson
Tel (425) 478-2121
Media Contact
Michael Tattory
LifeSci Communications
Tel (646) 751-4362
